Nick Abbott
Stock Analyst at Wells Fargo
(0.09)
# 4,736
Out of 5,043 analysts
27
Total ratings
11.8%
Success rate
-43.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nick Abbott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLLS Cellectis | Rated: Hold | $16 → $3 | $1.26 | +138.10% | 2 | Sep 15, 2026 | |
| ADAPY Adaptimmune Therapeutics plc | Reiterated: Hold | $1.5 | $0.03 | n/a | 1 | Oct 4, 2022 | |
| AFMDQ Affimed N.V. | Initiated Coverage: Buy | $18 → $8 | $0.0003 | n/a | 3 | Aug 18, 2022 | |
| IOVA Iovance Biotherapeutics | Initiated Coverage: Hold | $25 → $14 | $14.62 | n/a | 2 | Aug 18, 2022 | |
| STRO Sutro Biopharma | Initiated Coverage: Buy | $30 → $15 | $14.27 | n/a | 2 | Aug 18, 2022 | |
| CALA Calithera Biosciences, Inc. | Reiterated: Hold | $40 | $0.0001 | n/a | 1 | May 11, 2022 | |
| TCRT Alaunos Therapeutics | Upgraded: Buy | $3 | $0.7858 | n/a | 2 | May 4, 2022 | |
| ZYME Zymeworks | Reiterated: Buy | $45 | $25.79 | n/a | 2 | May 3, 2022 | |
| PGEN Precigen | Reiterated: Buy | $17 | $7.81 | n/a | 3 | Apr 13, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $107 → $105 | $13.74 | n/a | 3 | Mar 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $13 → $2 | $1.27 | n/a | 2 | Mar 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.18 | n/a | 2 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $0.000001 | n/a | 1 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $145 | $225.00 | n/a | 1 | Jun 29, 2021 |
Cellectis
Sep 15, 2026
Rated: Hold
Price Target: $16 → $3
Current: $1.26
Upside: +138.10%
Adaptimmune Therapeutics plc
Oct 4, 2022
Reiterated: Hold
Price Target: $1.5
Current: $0.03
Upside: n/a
Affimed N.V.
Aug 18, 2022
Initiated Coverage: Buy
Price Target: $18 → $8
Current: $0.0003
Upside: n/a
Iovance Biotherapeutics
Aug 18, 2022
Initiated Coverage: Hold
Price Target: $25 → $14
Current: $14.62
Upside: n/a
Sutro Biopharma
Aug 18, 2022
Initiated Coverage: Buy
Price Target: $30 → $15
Current: $14.27
Upside: n/a
Calithera Biosciences, Inc.
May 11, 2022
Reiterated: Hold
Price Target: $40
Current: $0.0001
Upside: n/a
Alaunos Therapeutics
May 4, 2022
Upgraded: Buy
Price Target: $3
Current: $0.7858
Upside: n/a
Zymeworks
May 3, 2022
Reiterated: Buy
Price Target: $45
Current: $25.79
Upside: n/a
Precigen
Apr 13, 2022
Reiterated: Buy
Price Target: $17
Current: $7.81
Upside: n/a
Arcturus Therapeutics Holdings
Mar 25, 2022
Reiterated: Buy
Price Target: $107 → $105
Current: $13.74
Upside: n/a
Mar 25, 2022
Downgraded: Hold
Price Target: $13 → $2
Current: $1.27
Upside: n/a
Aug 23, 2021
Reiterated: Buy
Price Target: n/a
Current: $2.18
Upside: n/a
Jul 28, 2021
Upgraded: Buy
Price Target: n/a
Current: $0.000001
Upside: n/a
Jun 29, 2021
Reiterated: Hold
Price Target: $145
Current: $225.00
Upside: n/a